CN Patent
CN102295576A — 替加环素的晶型及其制备方法
Assigned to 赵军旭 · Expires 2011-12-28 · 14y expired
What this patent protects
本发明属于医药技术领域,涉及替加环素的新晶型及其制备方法,其中A型替加环素结晶,其具有位于约5.0,8.2,9.2,10.2,11.3,13.0,13.7,18.7,20.5,21.8,24.0±0.2°2θ的X-射线粉末衍射峰;B型替加环素结晶,其具有位于约5.1,9.2,13.0,13.8,16.4,18.7,20.5,21.9,24.2±0.2°2θX-射线粉末衍射峰。
USPTO Abstract
本发明属于医药技术领域,涉及替加环素的新晶型及其制备方法,其中A型替加环素结晶,其具有位于约5.0,8.2,9.2,10.2,11.3,13.0,13.7,18.7,20.5,21.8,24.0±0.2°2θ的X-射线粉末衍射峰;B型替加环素结晶,其具有位于约5.1,9.2,13.0,13.8,16.4,18.7,20.5,21.9,24.2±0.2°2θX-射线粉末衍射峰。
Drugs covered by this patent
- Tygacil (TIGECYCLINE) · Fresenius Kabi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.